MAXCYTE, INC. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
MaxCyte reported Q2 2026 total revenue of $7.3M (down 15% from $8.5M in Q2 2025), with core revenue of $6.5M (down 21% YoY) and SPL program revenue of $0.8M (up 167% YoY). Net loss improved to $8.9M from $12.4M YoY. The company reiterated 2026 guidance of $30–32M total revenue and $130.5M+ cash position. Post-quarter, MaxCyte announced a strategic multi-platform technology license partnership with Genentech (unnamed deal size) providing access to the ExPERT GTx platform and complementary technologies. The company repurchased $5.5M of stock under a $10M authorized program.
Why this rating
Core revenue decline (21% YoY) is material for a $231M company; Genentech deal is strategically important but unquantified. Modest cash burn improvement. Positive SPL momentum offsets core decline.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.